← All trials
NCT06496217
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2024
- Primary completion
- Oct 12, 2024
- Completion date
- Oct 12, 2024
- First posted
- Jul 11, 2024
- Last posted
- Jul 18, 2024
- Enrollment
- 32
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MBX BiosciencesLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.